Navigation Links
Virobay Completes $8 Million Series B Preferred Stock Financing
Date:7/16/2014

MENLO PARK, Calif., July 16, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. Including this recent $8 million investment, Virobay has raised an aggregate of $18 million in two tranches of the Series B financing.  The first tranche was drawn in 2010.  Participants in the second tranche transaction include a syndicate of existing investors plus Perceptive Advisors, a dedicated healthcare fund.  Existing investors include TPG Biotechnology Partners, Alta Partners, Sutter Hill Ventures and Abbvie, Inc.  Additional terms of the financing were not disclosed.

Virobay expects to use proceeds from this offering to advance its clinical programs forward, specifically the clinical development of its lead product candidate, VBY-036, for the treatment of neuropathic pain.

"We are pleased that Perceptive Advisors joined our distinguished list of investors, and in addition, we appreciate the continued support of our existing investors," commented Dr. Robert Booth, President and Chief Executive Officer of Virobay. 

About Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule cysteine proteases inhibitors, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis. 
'/>"/>

SOURCE Virobay, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
2. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
5. CryoLife Completes Acquisition of Hemosphere
6. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
9. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
10. Ablative Solutions Completes $5.3M Series A Financing
11. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... Nov. 26, 2014 The medical magnetic ... rate of 4%, with world market revenues for ... MRI and other types of medical imaging have ... of numerous medical conditions in children and adults, ... Kalorama,s report, Medical Imaging Markets , analyzes ...
(Date:11/26/2014)... DALLAS , November 25, 2014 ... Surgical Instruments Market by Power Source (Electric, Battery, ... Console, Cables, Blade, Burr, Cart), by Application (Orthopedic, ... 2019" published by MarketsandMarkets, the global Powered Surgical Instruments ... to $1.6 Billion in 2014 and is expected ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
(Date:11/26/2014)... Bunion Bootie, the newest and best ... early celebration of the early holiday shopping season. Starting ... the promotional price of $29.95 each (normally $33.95 ea). ... any automatic discounts applied when buying more than one ... for complete details. It’s simple: purchasing more Bunion Booties ...
(Date:11/26/2014)... November 26, 2014 Louisiana Back ... and specialists in minimally invasive spine surgery, announces ... into the rapidly growing provider network of orthopedic ... addition coincides with the network’s continuing success providing ... for Louisiana residents who are suffering from orthopedic ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Youngsters who enter puberty ... study suggests. Early puberty was linked with a ... self-image and high anxiety levels, according to the researchers. ... as conflict with family and peers, and having friends ... found. Although the study found an association between ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... 19 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced ... scheduled for September 30,2007, will be held on December ... Arnon & Co., 1 Azrieli Center, Round Tower, 47th ... be asked to approve the previously,announced Asset Purchase Agreement ...
... may lower sperm count" do not tell the whole ... from the Harvard,School of Public Health in Boston presented ... was based on recollected intake,of soyfoods and not on ... issues, thus I feel the results should be viewed ...
... 18 West Pharmaceutical,Services, Inc. (NYSE: WST ... that it has decided to discontinue marketing the,Exubera ... the,Company,s customer, Nektar Therapeutics, Inc. The Company,s Tech ... Exubera inhalation device for Nektar. "We were ...
... Blocks inflammatory activity of two immune system molecules, researchers ... new twist on an old theory of drug treatment ... trial, a California company reports. , The idea is ... believed to play a major role in asthma by ...
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) ... of,privately held ForSight Newco II, Inc. Through this ... to commercialize,ForSight Newco II,s proprietary ocular punctal plug ... development efforts in this program. "We are ...
Cached Medicine News:Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3Health News:Real Men Eat Soy: The Truth about Soy and Sperm Count 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:New Drug Eases Asthma Symptoms 2Health News:New Drug Eases Asthma Symptoms 3Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 2Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 3
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: